The UK Health Security Agency (UKHSA) has secured a groundbreaking UK-based vaccine deal, strengthening the nation’s readiness for potential influenza pandemics
In an advance purchase agreement (APA), healthcare company CSL Seqirus commits to producing over 100 million influenza pandemic vaccines within the UK, ready for use in the event of a future pandemic declaration.
UK-based vaccine deal ensures greater access
Unlike previous agreements, this deal ensures the entire vaccine manufacturing process takes place in the UK, offering greater security and swifter access to vaccines should global demand surpass supply.
The vaccines will be tailored to combat the specific pandemic flu strain identified at the time, undergoing rigorous testing, licensing, and approval processes.
A milestone in pandemic preparedness
Professor Dame Jenny Harries, Chief Executive of UKHSA, emphasizes the significance of this agreement, citing past pandemic events such as COVID-19 and the critical role of vaccines in saving lives and minimizing disruptions.
Vaccines Minister Maria Caulfield highlights that this UK-based production will ensure a rapid response, potentially saving thousands of lives during an influenza pandemic.
Marc Lacey, Global Executive Director at CSL Seqirus, reaffirms the company’s commitment to pandemic preparedness, reinforcing the UK’s ability to respond swiftly to potential threats.
A history of pandemic concerns
While seasonal influenza and avian influenza have distinct characteristics, a novel influenza strain with global transmission potential poses the risk of a pandemic.
Historical data shows that influenza pandemics, such as those in 1918, 1957, 1968, and 2009, can occur unpredictably and have substantial global impacts.
The 1918 pandemic alone resulted in over 50 million deaths worldwide, underscoring the significance of pandemic influenza as a primary health security concern.
In summary, the UKHSA’s new UK-based vaccine deal with CSL Seqirus represents a significant stride in the nation’s preparedness for potential influenza pandemics, ensuring rapid access to tailored vaccines produced domestically in response to global health threats.
